Stock Research for ACOR

ACOR

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ACOR Stock Chart & Research Data

The ACOR chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACOR chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ACOR Due diligence Resources & Stock Charts

The ACOR stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACOR Detailed Price Forecast - CNN Money CNN View ACOR Detailed Summary - Google Finance
Yahoo View ACOR Detailed Summary - Yahoo! Finance Zacks View ACOR Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View ACOR Trends & Analysis - Trade-Ideas Barrons View ACOR Major Holders - Barrons
NASDAQ View ACOR Call Transcripts - NASDAQ Seeking View ACOR Breaking News & Analysis - Seeking Alpha
Spotlight View ACOR Annual Report - CompanySpotlight.com OTC Report View ACOR OTC Short Report - OTCShortReport.com
TradeKing View ACOR Fundamentals - TradeKing Charts View ACOR SEC Filings - Bar Chart
WSJ View Historical Prices for ACOR - The WSJ Morningstar View Performance/Total Return for ACOR - Morningstar
MarketWatch View the Analyst Estimates for ACOR - MarketWatch CNBC View the Earnings History for ACOR - CNBC
StockMarketWatch View the ACOR Earnings - StockMarketWatch MacroAxis View ACOR Buy or Sell Recommendations - MacroAxis
Bullish View the ACOR Bullish Patterns - American Bulls Short Pains View ACOR Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View ACOR Stock Mentions - StockTwits PennyStocks View ACOR Stock Mentions - PennyStockTweets
Twitter View ACOR Stock Mentions - Twitter Invest Hub View ACOR Investment Forum News - Investor Hub
Yahoo View ACOR Stock Mentions - Yahoo! Message Board Seeking Alpha View ACOR Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for ACOR - SECform4.com Insider Cow View Insider Transactions for ACOR - Insider Cow
CNBC View ACOR Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACOR - OTC Markets
Yahoo View Insider Transactions for ACOR - Yahoo! Finance NASDAQ View Institutional Holdings for ACOR - NASDAQ


Stock Charts

FinViz View ACOR Stock Insight & Charts - FinViz.com StockCharts View ACOR Investment Charts - StockCharts.com
BarChart View ACOR Stock Overview & Charts - BarChart Trading View View ACOR User Generated Charts - Trading View


Latest Financial News for ACOR

New Strong Sell Stocks for April 18th
Posted on Wednesday April 18, 2018

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:


See what the IHS Markit Score report has to say about Acorda Therapeutics Inc.
Posted on Monday April 16, 2018

The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding ACOR totaled $491 million.


Acorda to Present New Data For INBRIJA™ (levodopa inhalation powder) at 70th American Academy of Neurology Annual Meeting
Posted on Monday April 16, 2018

Acorda Therapeutics, Inc. will present new data for INBRIJA during four oral platform presentations at the upcoming American Academy of Neurology Annual Meeting in Los Angeles, taking place April 21–27, 2018.


How Analysts Rate Regenxbio and Peers in April 2018
Posted on Friday April 13, 2018

Regenxbio (RGNX) is a clinical-stage biotechnology company focused on developing gene therapy product candidates to address genetic defects. The company’s product candidate RGX-314 is designed for the treatment of wet age-related macular degeneration (or wet AMD), which is a leading cause of total and partial vision loss in the US, Europe, and Japan. The other promising product candidate in Regenxbio’s pipeline is RGX-501 for the treatment of homozygous familial hypercholesterolemia (or HoFH).


Enter a stock symbol to view the stock details.